Rabies post-exposure prophylaxis of international travellers - Results from two major German travel clinics
Saffar F, Heinemann M, Heitkamp C, Stelzl D, Ramharter M, Schunk M, Rothe C, Bühler S
TRAVEL MED INFECT DI. 2023;53:.

Reisevorbereitungen für Patienten mit Psoriasis unter Immunsuppression
Stephan B, Tittelbach J, Bühler S
J DTSCH DERMATOL GES. 2021;19(2):197-208.

TOURIST2 - Tracking of urgent risks in swiss travellers to the 6 main travel destinations - Feasibility and ethical considerations of a smartphone application-based study
Baroutsou V, Hatz C, Blanke U, Haile S, Fehr J, Neumayr A, Puhan M, Bühler S
TRAVEL MED INFECT DI. 2020;39:101912.

Safety and immunogenicity of a primary yellow fever vaccination under low-dose methotrexate therapy-a prospective multi-centre pilot study1
Bühler S, Jaeger V, Eperon G, Furrer H, Fux C, Jansen S, Neumayr A, Rochat L, Schmid S, Schmidt-Chanasit J, Staehelin C, de Visser A, Visser L, Niedrig M, Hatz C
J TRAVEL MED. 2020;27(6):taaa126.

Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals
Burkhard J, Ciurea A, Gabay C, Hasler P, Müller R, Niedrig M, Fehr J, Villiger P, Visser L, de Visser A, Walker U, Hatz C, Bühler S
VACCINE. 2020;38(19):3610-3617.

Rabies exposure in travellers to Asia, the Middle East, Africa, South and Central America-a German Airport study
Heitkamp C, Stelzl D, Ramharter M, Bühler S
J TRAVEL MED. 2020;27(7):taaa058.

Vaccination in Patients with Inflammatory Bowel Diseases
Manser C, Maillard M, Rogler G, Schreiner P, Rieder F, Bühler S
DIGESTION. 2020;101 Suppl 1:58-68.

Measles, Vaccines, and Types of Perception Bias in Public Debates
Mischlinger J, Muranaka R, Bühler S, Ramharter M
CLIN INFECT DIS. 2020;70(6):1258-1259.

Imported Malaria in countries where malaria is not endemic A comparison of semi-immune and nonimmune travelers
Mischlinger J, Rönnberg C, Álvarez-Martínez M, Bühler S, Paul M, Schlagenhauf P, Petersen E, Ramharter M
CLIN MICROBIOL REV. 2020;33(2):.

Reiseimpfungen
Rothe C, Boecken G
BUNDESGESUNDHEITSBLA. 2020;63(1):74-84.

Travel patterns, risk behaviour and health problems of travellers with rheumatic diseases compared to controls: A multi-centre, observational study
Schmid N, Ciurea A, Gabay C, Hasler P, Fehr J, Müller R, Villiger P, Walker U, Hatz C, Bühler S
TRAVEL MED INFECT DI. 2020;38:101818.

Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study
Bühler S, Jaeger V, Adler S, Bannert B, Brümmerhoff C, Ciurea A, Distler O, Franz J, Gabay C, Hagenbuch N, Herzog C, Hasler P, Kling K, Kyburz D, Müller R, Nissen M, Siegrist C, Villiger P, Walker U, Hatz C
RHEUMATOLOGY. 2019;58(9):1585-1596.

Flucelvax Tetra: a surface antigen, inactivated, influenza vaccine prepared in cell cultures
Bühler S, Ramharter M
ESMO OPEN. 2019;4(1):e000481.

Safety of live vaccines on immunosuppressive or immunomodulatory therapy-a retrospective study in three Swiss Travel Clinics
Huber F, Ehrensperger B, Hatz C, Chappuis F, Bühler S, Eperon G
J TRAVEL MED. 2018;25(1):.

Letzte Aktualisierung aus dem FIS: 24.04.2024 - 03:09 Uhr